谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

PROPEL: A Phase 1/2 Trial of NKTR-214 (Cd122-Biased Agonist) Combined with Anti-Pd-1 (pembrolizumab) or Anti-Pd-l1 (atezolizumab) in Patients (pts) with Advanced Solid Tumors.

Daniel A. Vaena,Jorge Chaves,Nicholas J. Vogelzang,Marc Ryan Matrana,A. Eli Gabayan,Matthew John Riese,Daniel C. Cho,Mary Ann Tagliaferri,Jonathan Zalevsky,Sunny Xie,Ute Hoch,Ahsan Naqi Rizwan,Sandra Aung,Michael Imperiale,James K. Schwarz

JOURNAL OF CLINICAL ONCOLOGY（2018）

引用 2|浏览73
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要